Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday?

Bristol Myers Squibb & Co (NYSE:BMY) on Monday announced topline data from the Phase 3 ODYSSEY-HCM trial of Camzyos (mavacamten) for symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy (nHCM). The trial did not meet its dual primary endpoints of…